title: HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.
abstract: The amino acid at position 36 of the HIV-1 protease differs among various viral subtypes, in that methionine is usually found in subtype B viruses but isoleucine is common in other subtypes. This polymorphism is associated with higher rates of treatment failure involving protease inhibitors (PIs) in non-subtype B-infected patients. To investigate this, we generated genetically homogeneous wild-type viruses from subtype B, subtype C, and CRF02_AG full-length molecular clones and showed that subtype C and CRF02_AG I36 viruses exhibited higher levels of resistance to various PIs than their respective M36 counterparts, while the opposite was observed for subtype B viruses. Selections for resistance with each variant were performed with nelfinavir (NFV), lopinavir (LPV), and atazanavir (ATV). Sequence analysis of the protease gene at week 35 revealed that the major NFV resistance mutation D30N emerged in NFV-selected subtype B viruses and in I36 subtype C viruses, despite polymorphic variation. A unique mutational pattern developed in subtype C M36 viruses selected with NFV or ATV. The presence of I47A in LPV-selected I36 CRF02_AG virus conferred higher-level resistance than L76V in LPV-selected M36 CRF02_AG virus. Phenotypic analysis revealed a >1,000-fold increase in NFV resistance in I36 subtype C NFV-selected virus with no apparent impact on viral replication capacity. Thus, the position 36 polymorphism in the HIV-1 protease appears to have a differential effect on both drug susceptibility and the viral replication capacity, depending on both the viral subtype and the drug being evaluated.
authors.affiliation: McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
authors.forename: Irene
authors.initials: I
authors.lastname: Lisovsky
authors.forename: Susan M
authors.initials: SM
authors.lastname: Schader
authors.forename: Jorge-Luis
authors.initials: JL
authors.lastname: Martinez-Cajas
authors.forename: Maureen
authors.initials: M
authors.lastname: Oliveira
authors.forename: Daniela
authors.initials: D
authors.lastname: Moisi
authors.forename: Mark A
authors.initials: MA
authors.lastname: Wainberg
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000069446:Atazanavir Sulfate; D002460:Cell Line; D002478:Cells, Cultured; D003062:Codon / Q000235:genetics*; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics / Q000821:virology; D016333:HIV Protease / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology* / Q000502:physiology; D006801:Humans; D061466:Lopinavir; D019888:Nelfinavir / Q000627:therapeutic use; D009842:Oligopeptides / Q000627:therapeutic use; D011110:Polymorphism, Genetic / Q000235:genetics*; D011725:Pyridines / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D003062:Codon; D009842:Oligopeptides; D011725:Pyridines; D011744:Pyrimidinones; D061466:Lopinavir; D000069446:Atazanavir Sulfate; D016333:HIV Protease; C514803:p16 protease, Human immunodeficiency virus 1; D019888:Nelfinavir
references.citation: AIDS. 2006 Oct 24;20(16):W13-23
references.pmid: 17053344
references.citation: Antimicrob Agents Chemother. 2006 Jun;50(6):2210-3
references.pmid: 16723586
references.citation: Antimicrob Agents Chemother. 2006 Feb;50(2):694-701
references.pmid: 16436728
references.citation: N Engl J Med. 2004 Mar 4;350(10):1023-35
references.pmid: 14999114
references.citation: AIDS. 2004 Apr 9;18(6):909-15
references.pmid: 15060438
references.citation: AIDS Rev. 2003 Jul-Sep;5(3):165-71
references.pmid: 14598565
references.citation: J Virol. 1997 Sep;71(9):6662-70
references.pmid: 9261388
references.citation: Antimicrob Agents Chemother. 2004 Jun;48(6):2159-65
references.pmid: 15155216
references.citation: Trop Med Int Health. 2008 Feb;13(2):144-51
references.pmid: 18304259
references.citation: Proc Natl Acad Sci U S A. 2001 May 22;98(11):6062-7
references.pmid: 11353856
references.citation: J Virol. 1996 Jun;70(6):3763-9
references.pmid: 8648711
references.citation: N Engl J Med. 2008 Apr 10;358(15):1590-602
references.pmid: 18403767
references.citation: PLoS Med. 2005 Apr;2(4):e112
references.pmid: 15839752
references.citation: AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1083-7
references.pmid: 11485626
references.citation: J Clin Virol. 2006 Aug;36(4):264-71
references.pmid: 16765636
references.citation: Pediatr Infect Dis J. 2005 Dec;24(12):1072-6
references.pmid: 16371868
references.citation: Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
references.pmid: 12019106
references.citation: Antiviral Res. 2007 Dec;76(3):203-21
references.pmid: 17673305
references.citation: Nat Rev Microbiol. 2007 Feb;5(2):141-51
references.pmid: 17203103
references.citation: Antimicrob Agents Chemother. 2005 May;49(5):1739-44
references.pmid: 15855490
references.citation: J Mol Biol. 2007 Jul 13;370(3):598-607
references.pmid: 17524421
references.citation: AIDS Rev. 2008 Oct-Dec;10(4):212-23
references.pmid: 19092977
references.citation: J Virol. 1998 Apr;72(4):2855-64
references.pmid: 9525605
references.citation: J Virol. 2002 Aug;76(15):7398-406
references.pmid: 12097552
references.citation: J Virol. 1986 Aug;59(2):284-91
references.pmid: 3016298
references.citation: AIDS Res Hum Retroviruses. 1999 Sep 20;15(14):1321-4
references.pmid: 10505681
references.citation: Science. 2000 Apr 7;288(5463):55-6
references.pmid: 10766634
references.citation: J Clin Microbiol. 1994 Aug;32(8):2000-2
references.pmid: 7527427
references.citation: Antiviral Res. 2002 Nov;56(2):129-42
references.pmid: 12367719
references.citation: J Infect Dis. 2004 Jun 1;189(11):1983-7
references.pmid: 15143463
references.citation: J Virol. 2001 Aug;75(16):7462-9
references.pmid: 11462018
references.citation: J Virol. 2007 Oct;81(19):10209-19
references.pmid: 17634242
references.citation: AIDS. 2006 Mar 21;20(5):643-51
references.pmid: 16514293
references.citation: Biochemistry. 2003 Dec 30;42(51):15029-35
references.pmid: 14690411
references.citation: Structure. 2005 Dec;13(12):1887-95
references.pmid: 16338417
references.citation: Curr Drug Metab. 2004 Aug;5(4):321-8
references.pmid: 15320704
references.citation: Br Med Bull. 2001;58:19-42
references.pmid: 11714622
references.citation: AIDS. 2003 Jan 3;17(1):F1-5
references.pmid: 12478089